ストックスクリーナーアプリを入手
7.66
2.54%
-0.20
アフターアワーズ：
7.64
-0.02
-0.26%
前日終値:
$7.86
開ける：
$7.81
24時間の取引高:
761.28K
Relative Volume:
31.11
時価総額：
$10.67M
収益：
-
当期純損益:
-
株価収益率:
-8.0336
EPS:
-0.9535
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+3,635%
1か月 パフォーマンス:
+3,635%
6か月 パフォーマンス:
+3,635%
1年 パフォーマンス:
+3,635%
1日の値動き範囲:
$7.61
$7.81
1週間の範囲:
$7.61
$8.1199
52週間の値動き範囲:
$7.61
$8.1199
Brooklyn Immunotherapeutics Inc Stock (BTX) Company Profile
名前
Brooklyn Immunotherapeutics Inc
セクター
電話
212 582 1199
住所
Building A, Suite 2100 140 58th Street, Brooklyn
BTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BTX
Brooklyn Immunotherapeutics Inc
|
7.66 | 10.67M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Brooklyn Immunotherapeutics Inc Stock (BTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-10-06 | 開始されました | Maxim Group | Buy |
Brooklyn Immunotherapeutics Inc (BTX) 最新ニュース
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - Defense World
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World
Eterna Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Eterna Therapeutics faces Nasdaq delisting over share price - Investing.com India
StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - Defense World
BNY Mellon Ultra Short Income ETF (NYSEARCA:BKUI) Stock Price Up 0% – Should You Buy? - Defense World
Athersys (NASDAQ:ATHX) Research Coverage Started at StockNews.com - Defense World
StockNews.com Begins Coverage on Avangrid (NYSE:AGR) - Defense World
General Electric (NYSE:GE) Shares Bought by Creative Planning - Defense World
Week Ahead (Apr.12- Apr.16): PDUFA Dates, Data Readouts (RCUS, ATXI, MRTX, KDNY…) - RTTNews
‘Today you’re going to die’. Man ‘disrespected’ at family event kills cousin, MN cops say - Kansas City Star
15-Year-Old Shot Outside Brooklyn High School: Police - Patch
Teen Shot Outside Brooklyn High School - BK Reader
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Has $87.23 Million Holdings in Intuit Inc. (NASDAQ:INTU) - MarketBeat
Eterna Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
Eterna Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Itau Unibanco Holding S.A. Takes Position in Bristol-Myers Squibb (NYSE:BMY) - Defense World
Video NYPD releases body camera video of police shooting at Brooklyn Subway station - ABC News
Brooklyn Farebeater Who Cops Shot Pleads Not Guilty From Hospital Bed - Brooklyn, NY Patch
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com - MarketBeat
Eterna Therapeutics sets September 27 for annual meeting - Investing.com
Exclusive: RNA firm Eterna Therapeutics buys neighboring startup for $50M - The Business Journals
Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights - GlobeNewswire
Kevin D’Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer - Business Wire
ERNA Stock Price and Chart — NASDAQ:ERNA - TradingView
Eterna Therapeutics Completes Name Change, Acquires Option - GlobeNewswire
Brooklyn hails immunotherapy for achieving 'primary objective'—but fails the primary endpoint - Fierce Biotech
“Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy” published in Chemical Reviews, selected as VINSE Spotlight Publication - Vanderbilt University
SpyBiotech Appoints Mark Leuchtenberger as Chief Executive Officer - citybiz
iPSC-derived dopamine progenitor cell therapy in Parkinson’s disease - RegMedNet
Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement - StockTitan
Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index - StockTitan
Longeveron: A Meme Stock That Will Oscillate Before Dropping (NASDAQ:LGVN) - Seeking Alpha
New R&D Center Will Focus on Cell-based Therapies - Sickle Cell Disease News
7 Top-Rated Pharmaceutical Companies to Invest In for July - InvestorPlace
Swedish MPA Approves Atossa Therapeutics Inc (NASDAQ: ATOS) To Conduct Phase 2 Clinical Trial Of Oral Endoxifen To Reduce Mammographic Breast Density - BP Journal
10 Top Penny Stocks On Robinhood To Watch Right Now Before July 2021 - Penny Stocks
Brooklyn Immunotherapeutics Inc (NYSEAMERICAN: BTX) Incorporates R&D Center In Cambridge, Massachusetts To Develop mRNA-based Gene Editing/ Cellular Therapies - BP Journal
Brooklyn ImmunoTherapeutics Stock Rises After Novellus Therapeutics Buyout Deal - Benzinga
Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company’s Future During May 25, 2021 Shareholder Update Call - StockTitan
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing - Business Wire
Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc. - Business Wire
CDE China Grants IND Approval For Vicineum Of Sesen Bio Inc (NASDAQ:SESN) - BP Journal
Christopher Rohde, Ph.D. to Join Scientific Advisory Board of Brooklyn ImmunoTherapeutics - citybiz
Citius Pharmaceuticals Inc (NASDAQ:CTXR) Reports Strong Presence Of Clinical Trial Staff, Investigators, And Referring Physicians In A Webinar On Mino-Lok Phase 3 Clinical Trial - BP Journal
Brooklyn ImmunoTherapeutics: Time To Sell (NYSE:BTX) - Seeking Alpha
Brooklyn Immunotherapeutics Inc (BTX) 財務データ
Brooklyn Immunotherapeutics Inc (BTX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):